Rice Hall James & Associates LLC Increases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Rice Hall James & Associates LLC raised its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 649,630 shares of the company’s stock after acquiring an additional 49,000 shares during the quarter. Kiniksa Pharmaceuticals makes up 0.9% of Rice Hall James & Associates LLC’s portfolio, making the stock its 29th largest holding. Rice Hall James & Associates LLC owned 0.92% of Kiniksa Pharmaceuticals worth $16,234,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. CWM LLC lifted its holdings in Kiniksa Pharmaceuticals by 443.0% during the third quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. nVerses Capital LLC bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth $80,000. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals in the 1st quarter worth $71,000. Ashton Thomas Private Wealth LLC bought a new stake in Kiniksa Pharmaceuticals during the second quarter valued at about $100,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Kiniksa Pharmaceuticals by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock valued at $195,000 after acquiring an additional 3,076 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 112,692 shares of company stock worth $2,950,315. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ KNSA opened at $22.59 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $14.12 and a 12-month high of $28.15. The stock’s fifty day simple moving average is $25.57 and its two-hundred day simple moving average is $22.42.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same quarter in the prior year, the business posted ($0.20) earnings per share. The firm’s quarterly revenue was up 67.4% on a year-over-year basis. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on KNSA. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus price target of $34.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.